RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Agents that inhibit estrogen production, such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-positive breast cancers. However, although initial treatment with these agents is often successful, many women eventually relapse with drug-resistant breast cancers. To overcome some of the challenges associated with current endocrine therapies and to combat the development of resistance, there is a need for more durable and more effective ER-targeted therapies. Here we describe and characterize a novel, orally bioavailable small-molecule selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer. RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation. Importantly, RAD1901 produced a robust and profound inhibition of tumor growth in MCF-7 xenograft models. In an intracranial MCF-7 model, RAD1901-treated animals survived longer than those treated with either control or fulvestrant, suggesting the potential benefit of RAD1901 in the treatment of ER-positive breast cancer that has metastasized to the brain. Finally, RAD1901 preserved ovariectomy-induced bone loss and prevented the uterotropic effects of E2, suggesting that it may act selectively as an agonist in bone but as an antagonist in breast and uterine tissues. RAD1901 is currently under clinical study in postmenopausal women with ER-positive advanced breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E., Ariazi, J., Cordera, F., & Jordan, V. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776173483 · Cited by 255
Research works printed but not linked: 18
- Yager, 2006, Estrogen carcinogenesis in breast cancer., N Engl J Med, 354, 270, 10.1056/NEJMra050776 · DOI · Paper page
- Stein, 2006, Estrogen-related receptor alpha as a therapeutic target in cancer., Endocr Relat Cancer, 13, S25, 10.1677/erc.1.01292 · DOI · Paper page
- Yue, 2013, Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis., Steroids, 78, 161, 10.1016/j.steroids.2012.11.001 · DOI · Paper page
- Stingl, 2011, Estrogen and progesterone in normal mammary gland development and in cancer., Horm Cancer, 2, 85, 10.1007/s12672-010-0055-1 · DOI
- Pinkerton, 2014, Use of SERMs for treatment in postmenopausal women., J Steroid Biochem Mol Biol, 142, 142, 10.1016/j.jsbmb.2013.12.011 · DOI
- Swaby, 2007, SERMs for the treatment and prevention of breast cancer., Rev Endocr Metab Disord, 8, 229, 10.1007/s11154-007-9034-4 · DOI
- Jordan, 2007, Chemoprevention of breast cancer with selective oestrogen-receptor modulators., Nat Rev Cancer, 7, 46, 10.1038/nrc2048 · DOI · Paper page
- Di Leo, 2010, . Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer., J Clin Oncol, 28, 4594, 10.1200/JCO.2010.28.8415 · DOI · Paper page
- Van Kruchten, 2015, . Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer., Cancer Discov, 5, 72, 10.1158/2159-8290.CD-14-0697 · DOI · Paper page
- Evans, 1988, The steroid and thyroid hormone receptor superfamily., Science, 240, 889, 10.1126/science.3283939 · DOI · Paper page
- Singh, 2005, Steroid hormone receptor signaling in tumorigenesis., J Cell Biochem, 96, 490, 10.1002/jcb.20566 · DOI
- McDonnell, 2002, Connections and regulation of the human estrogen receptor., Science, 296, 1642, 10.1126/science.1071884 · DOI · Paper page
- Burns, 2012, Estrogen receptors and human disease: an update., Arch Toxicol, 86, 1491, 10.1007/s00204-012-0868-5 · DOI · Paper page
- Herynk, 2007, Estrogen receptors in resistance to hormone therapy., Adv Exp Med Biol, 608, 130, 10.1007/978-0-387-74039-3_10 · DOI
- Kalu, 1991, The ovariectomized rat model of postmenopausal bone loss., Bone Miner, 15, 175, 10.1016/0169-6009(91)90124-I · DOI · Paper page
- Lai, 2015, . Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts., J Med Chem, 58, 4888, 10.1021/acs.jmedchem.5b00054 · DOI · Paper page
- Wardell, 2011, The turnover of estrogen receptor by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy., Biochem Pharmacol, 82, 122, 10.1016/j.bcp.2011.03.031 · DOI · Paper page
- Maximov, 2013, The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice., Curr Clin Pharmacol, 8, 135, 10.2174/1574884711308020006 · DOI · Paper page
Cited by
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Fanning, S. W., Mayne, C. G., Dharmarajan, V., Carlson, K. E., Martin, T. A., Novick, S. J., Toy, W., Green, B., Panchamukhi, S., Katzenellenbogen, B. S., et al. (2016) · eLife · doi:10.7554/elife.12792 · Cited by 314
Metadata
- Authors
- Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G.
- Venue
- Anti-Cancer Drugs
- Published
- 2015-10
- Volume
- 26
- Issue
- 9
- Pages
- 948-956
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W2395038895
- Cited by
- 157
- References
- 1
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. https://app.cochat.ai/papers/10.1097/cad.0000000000000271
- The paper
- Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G. (2015). RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0000000000000271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.